ArticleGeroScience2026
Treatment with a selective androgen receptor modulator (RAD140) is linked to better cardiac function, with male-specific effects that are graded by interleukin-6.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Low testosterone levels are associated with impaired cardiac function and elevated circulating inflammatory markers, which are mechanistically related. Selective androgen receptor (AR) modulators (SARMs) can stimulate ARs and mimic testosterone. Whether SARMs affect cardiac structure or function and if circulating inflammatory markers grade these changes is unclear. We investigated the effects of a SARM (RAD140) on cardiac function and structure in older male and female mice and explored how systemic inflammatory markers relate. Older (23-month-old) male and female mice were treated with RAD140 (5 mg/kg/day) for 6-weeks. Left ventricular (LV) structure and function were measured with echocardiography. Serum cytokine levels were assessed with a multiplex assay, and LV gene expression was tested. RAD140 treated males and females had higher ejection fraction (+ 10.4%), stroke volume (+ 9.6 µL) and cardiac output (+ 4.5 mL/min), versus controls. However, RAD140 treated males had better markers of cardiac function, including myocardial strain (-5.8%) and isovolumic relaxation times (-4.7 ms) compared to controls, with lesser or opposite effects in females. Higher levels of interleukin-6 correlated with worse global circumferential strain in males, but not females. qPCR analysis for genes coding proteins related to cardiac function and structure revealed no differences, although AR mRNA was lower with RAD140 treatment in both sexes. No structural differences were observed. RAD140 treatment may enhance cardiac function in older male mice, but less so in older female mice. Increased circumferential strain in males related to lower interleukin-6 levels, supporting the AR's connecting role between cardiac function and inflammatory markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.